Table 3.

Subgroup results of RFS and heterogeneity test

Variables	Analysis number	HR (95% CI)	Heterogeneity test
			Q	P	I2 (%)
Total RFS	7	1.331 (0.980 to 1.809)	9.48	0.148	36.7
Region
Asian	2	0.892 (0.454 to 1.752)	0.32	0.570	0.0
Caucasian	5	1.441 (1.014 to 2.047)	7.52	0.111	46.8
Sample size
>100	4	1.466 (0.986 to 2.181)	7.44	0.059	59.7
≤100	3	0.959 (0.534 to 1.725)	0.51	0.777	0.0
Follow-up (month)
≥60	3	1.036 (0.758 to 1.415)	0.79	0.674	0.0
<60	4	1.853 (1.316 to 2.607)	2.62	0.453	0.0
Stage
All NMIBC	3	1.575 (0.915 to 2.711)	4.44	0.109	54.9
Others	4	1.153 (0.821 to 1.620)	3.21	0.360	6.6
Cut-off
15%	2	1.625 (0.963 to 2.743)	0.31	0.575	0.0
Others	5	1.252 (0.839 to 1.869)	8.56	0.073	53.3
Publication year
≥2012	4	1.164 (0.874 to 1.550)	3.20	0.362	6.3
<2012	3	1.774 (1.046 to 3.008)	2.57	0.277	22.1
Patient age (year)
≥70	3	1.352 (0.955 to 1.913)	1.16	0.559	0.0
<70	4	1.256 (0.717 to 2.198)	8.32	0.040	63.9

NMIBC, non-muscle invasive bladder cancer; RFS, recurrence-free survival.